XPeng (NYSE:XPEV) Bolsa

XPeng

Founded in 2015, XPeng is a leading Chinese smart electric vehicle company that designs, develops, manufactures, and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 190,000 EVs in 2024, accounting for about 2% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.

News

NVDA

XPEV

Las acciones de NIO suben pese al llamado de Xi Jinping a frenar la inversión desordenada en IA y vehículos eléctricos en China.

Acciones de NIO suben pese a advertencia de Xi Jinping

Shanghai.china-july,2021:,Xpeng,Electric,Car,P7,At,Exhibition,Stand.,Xpeng

Tech

QCOM

XPeng abre pedidos en Europa de sus SUV G6 Ultra y G9 Ultra con plataforma 800V, carga del 10% al 80% en 12 min e IA avanzada.

XPeng abre pedidos en Europa para sus SUV G6 Ultra y G9 Ultra Smart

Shanghai,china-april,27,,2023:,Xpeng,Car,Logo,In,Shanghai,International,Automobile

Asia

Equities

Markets

Movers

General

Las acciones de XPeng bajan tras tensiones comerciales entre EE.UU. y China. Aun así, la marca lanza sus SUV G6 y G9 con mejoras clave.

XPeng cae en bolsa pese a lanzar sus nuevos SUV eléctricos G6 y G9 en Europa

WIIM

Qualcomm shares are trading lower following Q3 reported financial results.

Cognex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) is looking for Q3 Adj EPS of $0.24-$0.29 vs $0.24 analyst estimate. sees sales of $245.000 million-$265.000 million vs $250.071 million analyst estimate.

Guidance

CGNX

Cognex Sees Q3 Adj EPS $0.24-$0.29 vs $0.24 Est

Cognex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) sees Q3 sales of $245.000 million-$265.000 million vs $250.071 million analyst estimate.

Cognex Sees Q3 Sales $245.000M-$265.000M vs $250.071M Est

A 27-year-old nurse returned home from a trip to find himself in the middle of a financial standoff with his own mother. According to a recent Reddit <a href="https://www.reddit.com/r/Debt/comments/1lm5qxl/mom_wants_me_to_take_out_a_loan_to_pay_off_her/">post</a>, she asked him to take out a $50,000 loan to help her pay off $19,000 in debt and start a babysitting business.
He refused. Now she's calling him disloyal.
<h2 class="wp-block-heading">Reddit: Don't Do It</h2>
The poster explained, "I straight up said no as she does have a <a href="https://www.benzinga.com/personal-finance/management/25/07/46241860/kevin-oleary-slams-gen-zs-28-habit-that-could-cost-them-a-huge-sum-50-years-later-cant-stand-when-i-see-kids-making-70000-a-year-spending">spending habit</a> and also have my own expenses to care for." He's also in the process of buying property to rent out. Still, his family is pressuring him to at least take out $20,000 for her.
"I&#8217;ve been told that she will pay me back," he wrote, "but I know that my mom is terrible with managing money."
Don't Miss:
<ul class="wp-block-list">
<li>$100k+ in investable assets? <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning">Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes</a> – no cost, no obligation.</li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. You can <a href="https://www.benzinga.com/money/mode-mobile-2">invest today for just $0.30/share.</a></li>
</ul>
He also said the emotional manipulation started right away. &#8220;She has told me that she feels betrayed and that I do not trust her, which feels like I'm being gaslighted and guilt-tripped into doing this for her.&#8221;
Commenters on Reddit were nearly unanimous: Stand your ground.
&#8220;Not doing it is the correct option,&#8221; one person said. &#8220;Anyone that comes to you and says you need to do it, tell them they can do it if they feel so strongly.&#8221;
Another added, &#8220;If she can't pay back her loans to a company that can sue her and garnish wages, she certainly wouldn't pay back a pushover family member.&#8221;
One person cut straight to the point: &#8220;$20K loan will compound and <a href="https://www.benzinga.com/general/education/24/06/39156364/5-sure-ways-to-ruin-your-financial-health-according-to-ben-stein">ruin your financial life</a> for the next 5 years.&#8221;
Others shared personal stories about being pressured to financially support parents and how it wrecked their credit and relationships. Several said they ended up cutting their parents off completely to protect themselves.
Trending: Accredited Investors: Grab Pre-IPO Shares of the AI Company Powering Hasbro, Sephora &amp; MGM—<a href="https://www.benzinga.com/money/rad-intel">Just $0.63 Before NASDAQ Launch</a>
Another top comment warned, &#8220;You can always identify a boundary-stomper because they are the ones who act like victims when you set and actually enforce boundaries.&#8221;
Many offered suggestions instead of money. A few said they'd be willing to pay for a bankruptcy lawyer or help a parent sell valuables, but not take on debt in their name.
"Offer to help her with budgeting and financial planning and support to <a href="https://www.benzinga.com/money/how-to-stop-spending-money">limit spending</a>," one Redditor wrote. "Family that is encouraging you to take out a loan to ‘help her' is wrong. Doing so does not help her—it continues the problem."
The original poster made it known that he's staying firm: "I am going to stand my ground and not do it."
And most of Reddit agrees he should.
Read Next: The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?
Image: Shutterstock

Personal Finance

27-Year-Old Says His Mom Wants Him To Pay Her $50K In Debt. He Said No—Now She's Calling Him Disloyal, Even Though She's Terrible With Money

Biotech

MRNA

Moderna Receives European Commission Approval For The Updated COVID-19 Vaccine Formulating Targeting SARS-CoV-2 Variant LP.8.1

FMC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMC#NYSE">FMC</a>) reported quarterly earnings of $0.69 per share which beat the analyst consensus estimate of $0.61 by 13.11 percent. This is a 9.52 percent increase over earnings of $0.63 per share from the same period last year. The company reported quarterly sales of $1.05 billion which beat the analyst consensus estimate of $996.20 million by 5.40 percent. This is a 1.16 percent increase over sales of $1.04 billion the same period last year.

Earnings

Earnings Beats

FMC Q2 Adj. EPS $0.69 Beats $0.61 Estimate, Sales $1.05B Beat $996.20M Estimate

Cognex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) reported quarterly earnings of $0.25 per share which beat the analyst consensus estimate of $0.23 by 6.84 percent. This is a 8.7 percent increase over earnings of $0.23 per share from the same period last year. The company reported quarterly sales of $249.093 million which beat the analyst consensus estimate of $247.066 million by 0.82 percent. This is a 4.10 percent increase over sales of $239.292 million the same period last year.

Cognex Q2 Adj. EPS $0.25 Beats $0.23 Estimate, Sales $249.093M Beat $247.066M Estimate

IRVINE, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELDN#NASDAQ">ELDN</a>) today announced that the company will host a conference call and webcast on Wednesday, August 6, 2025 at 4:30 p.m. ET to discuss updated clinical data from its ongoing open-label Phase 1b study evaluating tegoprubart for the prevention of rejection in subjects undergoing kidney transplantation. These data, from approximately 30 kidney transplant recipients, are being presented at the World Transplant Congress (WTC) in San Francisco, CA on August 6, 2025.
To join the conference call, please dial 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers. The conference ID is 34575. Registration for the live webcast can be found <a href="https://www.globenewswire.com/Tracker?data=3JrgAzhSBhYstvbXFGx5R3mmItz_UqWQJGyms4gBq0XibWWPmGato81hLjYQVojHMfiN6FjoPSMjSNRNZhQxSQ6QKSThs8KiDNr7LmgIHMgh4VHeH37ZS1n9ZNwnnnMafMDSnRvblKc4JxX74QoXeOyzwu3jV1VgYleZ0tO_etaWRZeeQYfNa8Sk83us-CbYFnHzJfULv2zxKZMvqp4dQrGyCxjGp0V-KumLSvjY6tcbxyjqZZ2Qjn6AMuJI7ESunNKLgmM7m3_qegLWJN8ZFZdpAmg5KU126D9eMr_cdlHNmZLebOjQC9R-FEWb7ZdwhWs2USGkWmy9vB91tn4DGM6EwZVwsH2oTC3XsaoCftkpI3Bl4KBpnjD8k0x4zHSelxGscNAcyF7ry72VneIhZrbSkmiNy5EMTSnYgmOKk3Wf-BwHujzmwfALzOAEHBjE">here</a> and available on the "Events" section of Eledon's website at <a href="https://www.globenewswire.com/Tracker?data=DersPMxUYDUFfFAhj5nwVeX6vD855uh3LPXvGCDISQnzIuziQkyXm3lYEQJLObbF1S6hjQvKcoMvxFsKAXlmcvvzZlS8FceJCKGOc_l-fSsb1IWZtWCV_92TPP1klBI-_PgbB6_cJBEdrEyzL7NNeLrtx-hSHnyU4tBT6PiKPiptU2SErfpIhTiryyw7kueB0ErNebTDCIO6PQnaQ8C0Y6MoKRZsheJs6qrbgFWzL5WZB9mCn50v8akwb5y9nh12EpxWD9Ugw3Ms7uR-JoPXXdCzB0bvXqlsc1htDtMDDoiSNSUHGGSZImU-FJpt_NdsBZrKcz2ETins6L9CNxaw1L1gOst4G5S9mK-gr29p29y16_wZTh9AU55tctg1cwTW">www.eledon.com</a>. The webcast will be archived on the website following the completion of the call.

ELDN

Eledon Pharmaceutical To Host A Conference Call And Webcast On Wednesday, August 6, 2025 To Discuss Updated Clinical Data From Its Ongoing Open-label Phase 1b Study Evaluating Tegoprubart For The Prevention Of Rejection In Subjects Undergoing Kidney Transplantation

LRCX

Lam Research shares are trading higher after the company reported better-than-expected Q4 financial results.

Radian Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDN#NYSE">RDN</a>) reported quarterly earnings of $1.01 per share which beat the analyst consensus estimate of $0.98 by 3.38 percent. This is a 2.02 percent increase over earnings of $0.99 per share from the same period last year. The company reported quarterly sales of $237.520 million which missed the analyst consensus estimate of $238.933 million by 0.59 percent. This is a 0.09 percent decrease over sales of $237.731 million the same period last year.

Earnings Misses

Radian Group Q2 Adj. EPS $1.01 Beats $0.98 Estimate, Sales $237.520M Miss $238.933M Estimate

Howmet Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HWM#NYSE">HWM</a>) has outperformed the market over the past 5 years by 52.53% on an annualized basis producing an average annual return of 66.49%. Currently, Howmet Aerospace has a market capitalization of $77.56 billion. 
Buying $100 In HWM: If an investor had bought $100 of HWM stock 5 years ago, it would be worth $1,269.93 today based on a price of $192.14 for HWM at the time of writing.
<h3>Howmet Aerospace's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1753907413_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much $100 Invested In Howmet Aerospace 5 Years Ago Would Be Worth Today

Black Hills (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKH#NYSE">BKH</a>) affirms FY2025 GAAP EPS guidance from $4.00-$4.20 to $4.00-$4.20 vs $4.09 analyst estimate..

Black Hills Affirms FY2025 GAAP EPS Guidance of $4.00-$4.20 vs $4.09 Est

Alkami Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKT#NASDAQ">ALKT</a>) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.10) by 25 percent. This is a 360 percent decrease over earnings of $0.05 per share from the same period last year. The company reported quarterly sales of $112.10 million which beat the analyst consensus estimate of $110.01 million by 1.90 percent. This is a 36.44 percent increase over sales of $82.16 million the same period last year.

ALKT

Alkami Technology Q2 EPS $(0.13) Misses $(0.10) Estimate, Sales $112.10M Beat $110.01M Estimate

Dividends

HWKN

Hawkins Increases Quarterly Dividend From $0.18 To $0.19 Per Share

Service Corp Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCI#NYSE">SCI</a>) affirms FY2025 Adj EPS guidance from $3.70-$4.00 to $3.70-$4.00 vs $3.78 analyst estimate..

Service Corp Intl Affirms FY2025 Adj EPS Guidance of $3.70-$4.00 vs $3.78 Est

LIDR

AEye Regains Nasdaq Compliance

Rush Street Interactive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSI#NYSE">RSI</a>) raises FY2025 sales outlook from $1.010 billion-$1.080 billion to $1.050 billion-$1.100 billion vs $1.056 billion estimate.

Rush Street Interactive Raises FY2025 Sales Guidance from $1.010B-$1.080B to $1.050B-$1.100B vs $1.056B Est

Black Hills (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKH#NYSE">BKH</a>) reported quarterly earnings of $0.38 per share which missed the analyst consensus estimate of $0.39 by 1.3 percent. This is a 15.15 percent increase over earnings of $0.33 per share from the same period last year. The company reported quarterly sales of $439.000 million which beat the analyst consensus estimate of $412.680 million by 6.38 percent. This is a 9.04 percent increase over sales of $402.600 million the same period last year.

Black Hills Q2 EPS $0.38 Misses $0.39 Estimate, Sales $439.000M Beat $412.680M Estimate

<ul>
<li>iMDx first dd-PCR assay to combine relative and absolute measurements of dd-cfDNA into single combined score</li>
<li>Data show significantly improved positive predictive value (PPV) for graft rejection, which potentially broadens clinical utility for dd-cfDNA with fewer false positives, further reducing unnecessary invasive biopsies for patients</li>
<li>iMDx expects to evaluate combined score in ongoing FDA study (NCT07060716)</li>
<li>iMDx will be exhibiting at Booth #324 at the World Transplant Congress</li>
<li>National Principal Investigator and Key Opinion Leader call Friday, August 15th at 4 p.m. ET to discuss GraftAssureTM - branded family of assays</li>
</ul>

IMDX

Insight Molecular Diagnostics To Present Two Oral Abstracts At World Transplant Congress

Rush Street Interactive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSI#NYSE">RSI</a>) reported quarterly earnings of $0.11 per share which beat the analyst consensus estimate of $0.06 by 74.6 percent. This is a 175 percent increase over earnings of $0.04 per share from the same period last year. The company reported quarterly sales of $269.200 million which beat the analyst consensus estimate of $249.380 million by 7.95 percent. This is a 22.15 percent increase over sales of $220.379 million the same period last year.

Rush Street Interactive Q2 Adj. EPS $0.11 Beats $0.06 Estimate, Sales $269.200M Beat $249.380M Estimate

Press Releases

XPENG Unveils First Images of Next-Generation P7 Sports Sedan, Designed by Rafik Ferrag

XPENG Reports First Quarter 2025 Unaudited Financial Results

XPENG Announces MONA M03 Max and G7 SUV for Q2 2025, Showcasing AI Mobility Advances and 2026 Robotics Strategy

XPENG Redefines Mainstream EV Market with MONA M03 Max: World's Only AI-Powered Smart Driving at US$20,000

XPENG Announces Vehicle Delivery Results for May 2025

XPENG becomes the only Chinese automaker invited to present at the 2025 CVPR autonomous driving workshop

XPENG Announces Vehicle Delivery Results for June and First Half 2025

Insurance

SunCar and XPeng Enter a New Stage of Cooperation with the Launch of XPeng's G7 Model, Delivering Fully Intelligent Car Insurance to Drivers

XPENG Opens Order Books for All-New Smart Coupe SUV G6 and Smart Premium SUV G9 in Europe

XPENG Launches Global Localization Strategy in Indonesia with First Locally-produced X9 Delivery

AYRO

Cenntro

Chijet Motor Company, Inc. - Ordinary Shares

Chijet Motor Co

ECD Automotive Design, Inc. - Common Stock

ECD Automotive Design

Envirotech Vehicles

Ford Motor

Faraday Future Intelligent Electric Inc. - Class A Common Stock

Faraday Future

Fly-E Group

General Motors

Honda Motor Co

Lucid Group

Li Auto Inc. - American Depositary Shares

Li Auto

Lotus Technology Inc. - American Depositary Shares

Lotus Technology

NIO Inc. American depositary shares, each representing one Class A ordinary share

NWTN

Polestar Automotive Holding UK Limited - Class A ADS

Polestar Automotive

Polestar Automotive Holding UK Limited - Class C-1 ADS (ADW)

Rivian Automotive, Inc. - Class A Common Stock

Rivian Automotive

Thor Industries

Toyota Motor

Tesla

VinFast Auto

Winnebago Industries

Workhorse Gr

XPeng Inc. American depositary shares, each representing two Class A ordinary shares

ZEEKR Intelligent Technology Holding Limited American Depositary Shares (each representing ten (10) Ordinary Shares)

Comments

XPeng

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL